ARK 每周股评 – 6/25/2022

我们每周都会与投资者分享我们策略中一周内一天内升值或下跌超过15%的股票的周评。我们希望您觉得这篇评论有用。

We share weekly commentaries with investors on stocks in our strategies that have appreciated or dropped more than 15% in a day during the course of the week. We hope you find this commentary useful.

Accolade (ACCD)
+16%Shares of Accolade traded up over 16% on Thursday, tracking the broad market rally. Earlier this week, the healthcare benefits management company showcased its personalized approach to insurance plans to the conference of “Advocating for Health Insurance Providers” (AHIP).

注:周四,Accolade的股票交易上涨了16%以上,跟踪大盘的反弹。本周早些时候,这家医疗保健福利管理公司向 "倡导健康保险供应商"(AHIP)的会议展示了其个性化的保险计划方式。
Ginkgo Bioworks (DNA)
+18%Shares of Ginkgo Bioworks traded up 18% with Thursday’s broad market rally. We maintain our positive thesis on the Boston-based synthetic biology company and note that it recently acquired Bitome––a company specializing in real-time metabolite measurement––and reached a new research milestone in its collaboration with Cronos Group.

注:银杏生物公司的股票随着周四大盘的反弹上涨了18%。我们维持对这家位于波士顿的合成生物学公司的正面看法,并注意到它最近收购了Bitome--一家专门从事实时代谢物测量的公司--并在与Cronos集团的合作中达到了一个新的研究里程碑。
908 Devices (MASS)
+18%Shares of 908 Devices appreciated 18% alongside Thursday’s broad market rally, just two weeks after the company showcased to the American Society of Mass Spectrometry its protocols for expediting mass spectrometry procedures. 908 Devices is a life sciences tools company that miniaturizes mass spectrometry in order to decentralize chemical and biomolecular analysis.

注:908 Devices (MASS)公司的股票在周四的大盘反弹中升值了18%,就在该公司向美国质谱协会展示了其加快质谱分析程序的协议两周之后。908 Devices (MASS)公司是一家生命科学工具公司,它将质谱仪小型化,以分散化学和生物分子分析。
Veracyte (VCYT)
+16%Shares of Veracyte traded up over 16% during Thursday’s broad market rally, just days after the company demonstrated the efficacy of its Afirma Genomic Sequencing Classifier to improve the accuracy of thyroid cancer diagnosis. The pioneer in gene expression-based prognostic testing is one of the most vertically-integrated molecular testing companies on the market, in our view, and its decentralized testing portfolio (assays and instruments) should position the company to win significant share within and beyond the US.

注:Veracyte公司的股票在周四的大盘反弹中上涨了16%以上,就在该公司展示了其Afirma基因组测序分类器在提高甲状腺癌诊断准确性方面的功效之后。在我们看来,这家基于基因表达的预后测试的先驱是市场上最垂直整合的分子测试公司之一,其分散的测试组合(检测和仪器)应该使该公司在美国国内和国外赢得大量的份额。

主题测试文章,只做测试使用。发布者:star,转转请注明出处:https://wallstreetgm.com/ark-%e6%af%8f%e5%91%a8%e8%82%a1%e8%af%84-6-25-2022/

(0)
上一篇 2022年6月25日 下午5:11
下一篇 2022年6月28日 下午4:48

相关推荐

发表评论

您的电子邮箱地址不会被公开。